Physician profile
Edward D Discoe
NPI 1447252721
$2,129.36
in general payments reported to CMS, 2019-2025
33 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $126 · 2021: $348 · 2022: $251 · 2023: $186 · 2024: $279 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $367.76 | 2019-2022 | |
| Amgen INC. | $346.47 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $190.64 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $186.37 | 2019-2020 | |
| Lilly USA, LLC | $159.33 | 2022-2025 | Mounjaro, Jardiance |
| Abbvie INC. | $96.63 | 2021-2024 | Qulipta |
| Pfizer INC. | $85.34 | 2019-2025 | |
| Abbott Laboratories | $76.29 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.96 | 2020-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $61.54 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $57.23 | 2022-2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.94 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $37.81 | 2019-2024 | Bexsero |
| Astellas Pharma US INC | $28.40 | 2024 | Veozah |
| Amarin Pharma, INC. | $27.74 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.45 | 2022-2024 | Capvaxive, Vaxelis, Gardasil |
| Actelion Pharmaceuticals US, INC. | $22.70 | 2024 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $22.64 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $22.05 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $19.92 | 2022 | |
| Medicure Pharma INC. | $16.49 | 2021 | |
| Depuy Synthes Sales INC. | $15.92 | 2019 | |
| Esperion Therapeutics, INC. | $15.47 | 2024 | Nexletol |
| Avanir Pharmaceuticals, INC. | $14.54 | 2022 | |
| Baxter Healthcare | $14.07 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Mylan Specialty L.P. | $13.69 | 2020 | |
| Dexcom, INC. | $13.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.11 | 2023 | Leqvio |
| Kowa Pharmaceuticals America, INC. | $12.53 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.88 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.07 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Discoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.